The World Dementia Council has 24 members working across six continents. Council members are global leaders who work in research, academia, industry and civil society. They attend meetings, vote on key issues and participate in the organisation's work. The council also includes members who are living with dementia.

  • Harry Johns
    Harry Johns
    WDC Chair and Trustee

    Harry Johns is president and CEO of the Alzheimer's Association, the leader in Alzheimer's and dementia advocacy, research and support. Along with providing 24-hour care and support through its free Helpline, robust website and local services across the United States, the Association has achieved significant public policy advances and increases in federal research investments that have nearly tripled available funding. The Association's global leadership in research includes breakthroughs that have changed the trajectory of dementia research, with over $400 million invested in Alzheimer's research globally, $110 million at work today in 18 countries.


  • Jeremy Hughes
    Jeremy Hughes
    WDC Vice Chair and Trustee

    Jeremy Hughes works in health and social care and is former Chief Executive of the Alzheimer’s Society in the UK, where he led the charity in its five-year strategy “The New Deal on Dementia 2017-22”. He was awarded the CBE for services to older people in the Queen's Birthday Honours 2015.

  • Professor Ricardo F. Allegri, MD, PhD
    Professor Ricardo F. Allegri, MD, PhD
    WDC Member

    Professor Ricardo F. Allegri is Head of the Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology and Director of the Ageing and Memory Centre at the Neurological Research Institute Raúl Carrea (FLENI) in Buenos Aires. He is also Professor of Neurology in the School of Medicine at the University of Buenos Aires and is chair of the Scientific Council at the Association against Alzheimer's disease and related disorders in Argentina (ALMA).

    Professor Allegri has published extensively on cognitive neurology in neurological journals and books and has co-edited seven books, including, “Dementia: A Multidisciplinary Approach,” one of the most important books written in Spanish on this topic. He has received over 45 awards in the field of Cognitive Neurology and Neuropsychiatry, including the National Academy of Medicine Award in 2006 and the Research Recognition Award by the School of Medicine, University of Buenos Aires in 2014.

  • Professor Philippe Amouyel - MD, PhD
    Professor Philippe Amouyel, MD, PhD
    WDC Member

    Professor Philippe Amouyel is General Director of Fondation Plan Alzheimer and Professor of Epidemiology and Public Health at the University Hospital of Lille, France. Since 1998, Professor Amouyel has headed a research unit of 50 people dedicated to public health and the molecular epidemiology of age-related diseases. He has published more than 750 scientific articles and participated in the discovery of 20 confirmed genetic loci predisposing to sporadic Alzheimer’s disease.

    At the European level, Professor Amouyel also chairs the European Joint Programming Initiative on research on neurodegenerative diseases and Alzheimer’s in particular (JPND). The main objective of JPND is to combine the strength of European and global research to tackle these diseases more efficiently.

  • Paola Barbarino
    Paola Barbarino
    WDC Member

    Paola is the CEO of Alzheimer’s Disease International. Prior to that, she was CEO of LIFE. Her previous senior positions include Cass Business School, Tate, British Library and IIED.

    She is a Trustee of The Postal Museum and Lauderdale House. Previously she was a Trustee of Shelter, the UK housing and homelessness charity and of MLA London. She is also the Managing Director of Opaline Limited, a consultancy company specializing in strategy and governance.

     She holds a degree cum laude in Classics from the University of Napoli Federico II, an MA in Field and Analytical Techniques in Archaeology and an MA in Library and Information Science both from University College London.

  • Samantha Budd Haeberlein, PhD
    Samantha Budd Haeberlein, PhD
    WDC Member

    Dr. Samantha Budd Haeberlein is Vice President and Head of Alzheimer’s Clinical Development at Biogen and leads the team accountable for Global Clinical Development for their Alzheimer’s disease portfolio. She has over seventeen years of pharmaceutical industry experience across research, translational science/medicine and clinical development and is recognised internationally for leadership in Alzheimer’s disease drug discovery, diagnostics and clinical development. She is currently on the Board for The Boston Home, a residence and centre for the care of adults with advanced, progressive neurological diseases and has previously served on the Board for Rodin Therapeutics and the Stockholm Brain Institute. She previously worked at AstraZeneca in the US, Canada and Sweden, where she held a number of senior research and development roles in connection with Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.  

  • Hilary Doxford
    Hilary Doxford
    WDC Member

    Hilary Doxford is a former Vice Chair European Working Group of People with Dementia, Ambassador Alzheimer's Society speaking nationally and internationally as a person with dementia. She was diagnosed with early onset Alzheimer’s disease at the age of 53.

    Hilary Doxford also volunteers for the Alzheimer’s Society in England as part of their research network and user involvement programme; is a champion for “Join Dementia Research;” and is a member of Dementia Alliance International. She is a founder member of the UK Three Nations Dementia Working Group, established in 2017 to advocate for people with dementia and to collaborate with professionals working in the field.

  • Phyllis Ferrell
    Phyllis Ferrell
    WDC Member

    Phyllis Ferrell is the Vice President of the global Alzheimer’s team for Eli Lilly and Company. She and her team are responsible for the late-stage development and global registration of several treatments targeted for patients with Alzheimer’s disease. She has been with Eli Lilly for more than 20 years and has held many leadership roles throughout the organisation. She has led efforts in sales, marketing, alliance management, strategy, Six Sigma and corporate financial planning. She is also a member of the Indiana Chapter of the Healthcare Businesswomen’s Association and was recognised with their Rising Star Award in 2014. She is on the Boards of Directors for the Indiana Chapter of the Alzheimer’s Association and the Stanford Associate Board of Governors; and is a founding member of Women Against Alzheimer’s. 

  • Dr. Margaret A. Hamburg
    Margaret A. Hamburg, MD
    WDC Member

    Dr.  Margaret (Peggy) A. Hamburg is an internationally recognised leader in public health and medicine. She is the former Commissioner of the US Food and Drug Administration (FDA), having stepped down from that role in April 2015 after almost six years of service.

    Peggy Hamburg is President-elect of the American Association for the Advancement of Science and is an elected member of the Council on Foreign Relations and the National Academy of Sciences, where she serves as Foreign Secretary. She currently sits on the board of the Commonwealth Fund, the Simons Foundation, the Urban Institute and the American Museum of Natural History. She is also a member of the Harvard University Global Advisory Council and the Scientific Advisory Committee for the Bill and Melinda Gates Foundation.

  • Paul Hogan
    Paul Hogan
    WDC Member

    Paul Hogan founded Home Instead Senior Care® with his wife Lori in 1994. Today, the franchise network is the world's leading provider of home care services for seniors, with more than 1,100 independently owned and operated offices that provide more than 60 million hours of care annually across 12 countries on four continents. In addition to his work with the World Dementia Council, Hogan serves on the Board of Governors for the Global Health and Healthcare Partnership Community at the World Economic Forum (WEF) and had previously served as the Vice Chair for the Global Agenda Council on Ageing.

  •  Yves Joanette PhD, FCAHS
    Yves Joanette PhD, FCAHS
    WDC Member

    Dr Yves Joanette is Professor of Cognitive Neurosciences and Ageing for the Faculty of Medicine at the Université de Montréal, and is currently the Director of the Digital Health Consortium at the Université de Montréal. He is a former Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute of Ageing.

    Dr Joanette sits on many international advisory and management boards, including several European initiatives in which Canada participates, including the EU Joint Programme on Neurodegenerative Disease Research. He is a member of the Steering Committee of the Joint Programming Initiative: More Years, Better Lives; of the Advisory Board of the Milken Institute’s Centre for the Future of Ageing; and of the Global Council on Brain Health.

  •  Kiyoshi Kurokawa, MD, PhD
    Kiyoshi Kurokawa, MD, PhD
    WDC Member

    Dr. Kiyoshi Kurokawa is Chair, Health and Global Policy Institute; Professor, Emeritus of the University of Tokyo and National Graduate Institute for Policy Studies; Distinguished Research Affiliate, The MIT Media Lab; and Chair and Representative Director, Global Health Innovative Technology Fund.

    Dr. Kurokawa is well known internationally in the fields of medicine, health, science, technology and innovation policies through his leadership, including as President of the Science Council of Japan and Science Adviser to the Prime Minister and WHO Commissioner. He was professor at UCLA School of Medicine, Tokyo University and Dean of Tokai University School of Medicine. He has received many awards, including the AAAS Scientific Freedom and Responsibility award and a 100 Top Global Thinkers award for his leadership in the National Diet of Japan Fukushima Nuclear Accident Independent Investigation Commission.

  • Maryna Lehmann
    Maryna Lehmann
    WDC Member

    Maryna Lehmann was diagnosed with dementia in February 2018 at the age of 58, and lives in George, South Africa. She was born in Johannesburg, South Africa, in 1960. She is the eldest of 5 siblings and matriculated in 1977. She enrolled for a BSc (Agric.) at Pretoria University and completed the Honours Degree in 1981. She married the same year. Her husband, André, retired in February 2019 to take care of her.

    In January 1982 she was employed as a farm manager of 300 sow piggery, 400 extensive cattle, 3000 head in feedlot. In the next 18 years she reared 4 sons and taught in numerous agriculture schools. On 1 January 2000 she joined Nelson Mandela University, as the Animal Science lecturer and completed a Masters Degree in Animal Science. She received numerous accolades such as upcoming researcher and upcoming teacher in 2006 and also received the "overall" teacher of the year award in 2007.

  • Chris Llewellyn
    Chris Llewellyn
    WDC Member

    Chris Llewellyn is a Partner in McKinsey and Company, based in London. A surgeon by background, he has extensive knowledge and experience in healthcare. He is the Head of McKinsey’s Medical Products practice in EMEA and a leader in their Life Sciences research and development practice.

    Chris Llewellyn has worked with the President of Israel to plan a world-leading neurotechnology cluster and helped the then UK Prime Minister, David Cameron to develop a national life sciences strategy focusing on attracting investment and boosting employment in the sector and beyond.

  • Husseini Manji
    Husseini Manji, MD
    WDC Member

    Husseini K Manji, MD, FRCPC is Global Head, J&J Science for Minds, and immediate past Therapeutic Head for Neuroscience at Janssen Research & Development, one of the Johnson & Johnson pharmaceutical companies. His research has investigated disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. This has led to the FDA approval of the first novel antidepressant mechanism (NMDA-antagonism) in decades and has been actively involved in developing biomarkers to help refine these diseases. Dr Manji has been inducted into the National Academy of Medicine, the World Economic Forum Global Future Councils and is a member of Harvard/MIT’s Stanley Center SAB, amongst other appointments. He has received a number of awards including the NIMH Director's Career Award for Significant Scientific Achievement, and has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and development of novel therapeutics with over 300 publications in peer-reviewed journals, including Science and Nature Neuroscience. He is an Honorary Fellow at Oxford University and Visiting Professor at Duke University, and previously served as Chief of the Laboratory of Molecular Pathophysiology at the NIH as well as Director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world.

  • Tetsuyuki (Tetsu) Maruyama, PhD
    Tetsuyuki (Tetsu) Maruyama, PhD
    WDC Member

    Dr. Tetsu Maruyama is the Chief Scientific Officer at the Dementia Discovery Fund (DDF). His background is in neuroscience, working in academia and then in industry, where he was at Merck Sharpe and Dohme’s Neuroscience Research Centre in the UK and then at GSK, where he was the Director of the GSK Centre for Cognitive and Neurodegenerative Disorders in Singapore. In 2006, he moved to Takeda Pharmaceutical Company in Japan, as Head of CNS Research and then as Head of Global Drug Discovery, a position he held until his appointment to the DDF in April 2016.

  • Professor Pierluigi Nicotera, PhD
    Professor Pierluigi Nicotera, PhD
    WDC Member

    Professor Pierluigi Nicotera is Scientific Director and Chairman of the Executive Board of the German Center for Neurodegenerative Diseases, known as DZNE. He previously headed the Molecular Toxicology division at the University of Konstanz before becoming Director of the UK Medical Research Council Toxicology Unit.

    Professor Nicotera is a renowned scientist and leading international expert in the field of neuronal cell death. Loss of neuronal synaptic connections and apoptosis play central roles in neurodegenerative diseases and his research has focussed on the molecular mechanisms that lead to neuronal demise following chronic and acute insults.

  • Meera Pattabiraman
    Meera Pattabiraman
    WDC Member and Trustee

    Meera Pattabiraman is Chair of the Alzheimer’s and Related Disorders Society of India (ARDSI). She has been working in the field of dementia care, management and advocacy for the past 18 years. A post graduate in business administration, she entered the field of social work and dementia care because of her personal experience of being a carer for her father who had Alzheimer’s disease.

    Meera Pattabiraman was part of the editorial board that produced the India Dementia Report in 2010, which is now used by the Ministry of Health and the Ministry of Social Justice and Empowerment as the reference guide in all matters relating to dementia. She is also part of the national think tank to develop better healthcare for the elderly and has taken part in national health policy meetings.

  • Lorna Sabbia
    Lorna Sabbia
    WDC Member

    Managing Director Head of Retirement & Personal Wealth Solutions.Lorna Sabbia is a 23-year veteran with the firm and is currently Head of Retirement & Personal Wealth Solutions at Bank of America Merrill Lynch. Lorna is responsible for both the institutional and personal retirement capability set to include 401(k), Equity and Health Benefit plans for companies of all sizes as well as college savings, personal retirement planning, retirement income, insurance and estate planning for individuals. 

    Prior to this role, Lorna served as Head of Managed Solutions where she led the discretionary and non-discretionary fee-based investment platforms, the global mutual fund and ETF offerings across all channels, and relationship management with third-party investment partners. In addition, she drove the creation and implementation of Merrill Lynch One, the largest and most successful launch of an investment advisory platform in our firm’s history.Previous to this position, Lorna was Head of the Client Solutions Group, leading all Investments & Wealth Management and Wealth Structuring specialists and support desks, the Portfolio Strategies Desk, Annuity and Life Insurance Product management, in addition to the management of investment partner and insurance carrier relationships. 

    Before joining the Client Solutions Group, Lorna was Head of Sales and Marketing for Merrill Lynch Trust Company (now part of U.S. Trust), and from 2002 to 2006, she served as National Sales Manager for Merrill Lynch Investment Managers. She began her career at the company as a specialist for nearly eight years in two divisions, New York and New England, across three different disciplines.

    Lorna earned a Bachelor of Science degree in Business Administration from Boston University. She is Executive Sponsor of the company’s Diverse Leader Sponsorship Program, Co-Chairs the firm’s Global Diversity & Inclusion Council, and serves as Market Sponsor for the Knoxville market. In 2013, she was named to the “10 to Watch” list by REP. Magazine. She is also Chair Emeritus for the Money Management Institute’s Board of Governors. Finally, Lorna is a member of both the Women Against Alzheimer’s Leadership Council and the World Dementia Council.

  • Shekhar Saxena
    Professor Shekhar Saxena, MD
    WDC Member

    Dr Shekar Saxena is Professor of the Practice of Global Mental Health at Harvard T H Chan School of Public Health. He is a psychiatrist by training and has worked previously at World Health Organization for 20 years including as the Director of the Department of Mental Health and Substance Abuse, Geneva from 2010 to 2018. His expertise includes providing advice and technical assistance to policy makers on prevention and management of mental, developmental, neurological and substance use disorders and suicide prevention.  He led the WHO team for adoption of the first ever Mental Health Action Plan by the World Health Assembly in 2013. He also led the adoption of WHO Action Plan on Public Health Response to Dementia and its implementation.

  • Philip Scheltens
    Professor Philip Scheltens, MD, PhD
    WDC Member

    Professor Dr Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD (Magnetic Resonance Imaging in Alzheimer's disease) in 1993. Since 2000 he has been Professor of Cognitive Neurology and Director of the Alzheimer Center at Amsterdam University Medical Centers. His main clinical and research interests are Alzheimer's disease, vascular dementia, frontotemporal dementia, magnetic resonance imaging, PET imaging and fluid biomarkers. He is active in the field of biomarkers and clinical trials and has been the national PI for many studies, including phase 1-3 multicenter clinical trials. He founded and directs the Alzheimer Center since 2000, from which over 55 PhD theses have appeared since then. In 2013, he co-founded the Dutch national plan against dementia (Deltaplan Dementie) and serves as vice-chair of the board since then. He has authored over 950 peer reviewed publications and his H-factor is currently 103. In 2011, he was elected as member of the Royal Dutch Academy of Arts and Sciences (KNAW) and serves as Secretary General since 2015. In 2016 he was awarded the European Grand Prix for Alzheimer’s Research.

  • Li-Yu Tang
    Li-Yu Tang
    WDC Member

     Li-Yu Tang is Secretary General and co-founder of the Taiwan Alzheimer’s Disease Association (TADA),  and is a member of the Long-Term Care Committee of the Executive Yuan of Taiwan. She has over 28 years’ experience in dementia research, practice and training.

    While at TADA, Li-Yu Tang has set up a toll-free helpline service, caregiver support groups and training programmes and a national dementia social support centre. She has created health promotion programmes for people with dementia and their care givers and provided training and coaching to more than sixty organisations throughout the country to help them deliver the programmes. She is also a consultant to Taipei City Government and is a member of a long-term care committee of four city governments in Taiwan. 

  • George Vradenburg
    George Vradenburg
    WDC Member and Trustee

    George Vradenburg convenes the Global CEO Initiative on Alzheimer’s (CEOi), a patient-centered industry coalition working with government, researchers and patients to develop and deliver innovative medicines to those touched by dementia and improve their quality of care. He also chairs the Global Alzheimer's Platform Foundation (GAP) and is chair and co-founder of USAgainstAlzheimer’s (USA2), which convenes CEOi and is a “disruptive,” entrepreneurial and patient-focused US based NGO committed to stopping Alzheimer’s disease by 2020.

    USA2 also founded and leads GAP, the North American arm of a global initiative to re-engineer Alzheimer's clinical trials for greater speed, efficiency, quality and diversity; and co-convenes Leaders Engaged on Alzheimer’s Disease, a US-based 90+ member coalition of Alzheimer’s-serving organisations mobilising a movement to end Alzheimer's. George Vradenburg is also a member of the Council on Foreign Relations and the Economic Club of Washington, DC. Before his retirement, he served in senior executive positions at AOL/Time Warner, Fox and CBS.

  • Huali Wang
    Professor Huali Wang, MD, PhD
    WDC Member

    Dr Huali Wang is Professor and the Chair for Clinical Research, Director of the Dementia Care and Research Center, and Associate Director of Beijing Dementia Key Lab, Peking University Institute of Mental Health.

    She established the first dementia caregiver support group in China in 2000. Now she directs a training program for community doctors and service providers, and a train-the-trainer program for dementia caregivers support in China. She published five books on dementia care, including Smart Caregivers, China Memory Clinic Guideline and Practice Manual on Psychological Support for Older Adults. The care model has been partly adopted by WHO West Pacific Regional Office to develop the toolkit for community-based dementia care in low- and middle-income countries. Dr Wang is leading the National Platform on Clinical Dataset and Biobank of Major Mental Disorders. In regard to biomarker research of Alzheimer's Disease, she found that ApoE4 allele potentially modulates the hippocampal connectivity and the brain functional connectome.

    Huali also serves leading position in national and international mental health research and service advocacy, including Secretary of International Psychogeriatric Association, Vice President of Chinese Society of Geriatric Psychiatry (founding member), Executive Vice President of Alzheimer's Disease Chinese (member of ADI), and WHO Global Dementia Observatory Focal Point for China. Dr Wang obtained Bachelor of Medicine from Beijing Medical University in 1994, and MD/PhD from Peking University in 2001. She has also attended Harvard Medical School (2002, 2012), the University of California, Irvine (2002-2005), and Duke University (2013).

  • Our associate members

    Our associate members represent national governments, organizations such as the OECD and WHO and other international organizations. They help to ensure that WDC’s agenda aligns with other global dementia initiatives, providing the Council with important advice, guidance and intelligence.